Insight
Redefining quality of life: The role of non-invasive treatments in women’s health
By Gloria Kolb, Co-founder & CEO – Elitone

In women’s healthcare, the options for treating various conditions have traditionally leaned heavily toward surgical or pharmaceutical interventions.
While these treatments are effective in many cases, they often come with risks, downtime, and long-term side effects.
From surgeries that require lengthy recovery periods to medications with potential side effects that can disrupt daily life, these options can significantly impact a woman’s quality of life.
However, as healthcare evolves, so does the demand for more non-invasive solutions. Today, women seek alternatives that provide relief without compromising their lifestyles or health.
Non-invasive treatments offer a refreshing departure from conventional approaches that often prioritise more intrusive methods because they are designed to be less disruptive, allowing women to continue with their lives without significant interruptions.
Wearable treatments, lifestyle modifications, and other non-invasive options improve the overall quality of life in women’s health by prioritising their balance, well-being, and control.
The push toward surgical and pharmaceutical solutions
The traditional medical and pharmaceutical communities often lean toward surgical or pharmaceutical interventions for various reasons, not the least of which is profitability.
Surgical procedures and long-term pharmaceutical treatments are not only more lucrative for healthcare providers but also offer a clear-cut, often immediate, solution to certain health conditions.
For example, surgeries for conditions like incontinence, pelvic organ prolapse, or other women’s health issues are commonly marketed as a definitive “fix.”
Medications, meanwhile, are often prescribed to manage symptoms over the long term.
While this approach can create continued profits for pharmaceutical companies, clinicians do not prescribe medications with this in mind.
Rather, medications are often seen as a quick and straightforward solution: a prescription that gets a patient on their way with minimal effort required in the short term.
However, these solutions can come at a significant cost to the women undergoing them.
Surgical procedures can involve weeks of recovery, potential complications, and even repeat operations. They can be costly, and copays and deductibles are substantial.
Additionally, while pharmaceutical interventions can be less invasive than surgery, they often come with a range of side effects specific to the condition being treated.
For instance, medications for endometriosis or hormone replacement therapy can lead to weight gain, fatigue, or hormone imbalances, which can disrupt daily life and add stress for many women.
These trade-offs are often a source of frustration, as managing the side effects can feel like swapping one problem for another. Incorporating broader examples of women’s health issues, such as endometriosis, polycystic ovary syndrome (PCOS), or menopause, makes the conversation around treatment options more relatable and comprehensive.
What non-invasive treatments offer
Non-invasive treatments, by contrast, redefine what it means to manage health conditions.
While clinicians may define “non-invasive” as strictly non-surgical, the broader perspective includes treatments that avoid physical intrusion, require fewer clinician visits, and don’t demand significant time off work or logistical challenges like arranging transportation.
These hurdles often discourage women from completing or even starting the care they need.
Non-invasive options remove these barriers, making it more likely that women will adhere to and benefit from treatment.
In medical terms, this approach is often referred to as “conservative” treatment. The idea is to try solutions that don’t permanently alter the body or limit future options.
For example, once a surgical implant is placed, other procedures become more complicated or unavailable.
Conservative treatments, by contrast, allow women to explore other options later if needed.
Take, for example, wearable treatments for incontinence. These devices offer a discreet, non-invasive way to treat symptoms by strengthening the pelvic floor muscles over time.
Wearable treatments don’t require surgery or even any downtime. Women can go about with their tasks while getting treatment.
Furthermore, women don’t have to wear the device all day — it only takes up to 20 minutes — and many of these non-invasive options are designed to address multiple conditions beyond incontinence, including pelvic pain, hormonal imbalances, or menstrual irregularities.
By working with the body’s natural rhythms, they offer a gentler alternative to conventional treatments.
This alignment with the body allows women to feel in control of their health, pursuing treatment that supports their needs without dominating their lives.
Redefining quality of life for women
Quality of life is a concept that extends beyond simply managing symptoms.
It encompasses a woman’s overall well-being and ability to engage fully in her relationships, work, and personal interests without being hindered by her health.
Non-invasive treatments offer solutions that respect this broader definition of wellness.
For instance, non-invasive treatments such as pelvic floor therapy or low-impact physical therapies can help women regain control of their bodies without the need for surgery.
These treatments encourage gradual, natural improvement over time, allowing women to recover strength and function at their own pace.
There’s no need for a significant disruption to daily life. which is particularly important for women who balance multiple roles — whether in the workforce, at home, or both.
Similarly, lifestyle modifications such as dietary changes, stress management techniques, or even behavioral therapies can be instrumental in managing women’s health conditions without the need for aggressive treatments.
These approaches support physical health and mental and emotional well-being, reinforcing the idea that quality of life is multidimensional.
When women have access to non-invasive treatments, they are empowered to make choices about their healthcare that prioritise their personal and professional lives.
This is crucial in an era when women are managing more than ever — family, career, personal development, and health.
Non-invasive treatments offer a way to balance these aspects without sacrificing well-being.
The future of non-invasive treatments in women’s health
As more women demand non-invasive options, the healthcare landscape is gradually shifting.
Wearable devices, digital health solutions, and other innovations make it easier for women to take control of their health without feeling like their condition controls them.
In particular, the rise of Femtech — technology designed to address women’s health issues — has brought an array of non-invasive options to the forefront.
From wearable treatments for pelvic floor strengthening to apps that track and manage menstrual cycles, to cooling mechanisms for hot flashes, and digital solutions for hormone balance, these innovations prioritise convenience and accessibility.
The future of women’s health lies in individualised, non-intrusive care.
These advancements offer women the opportunity to prioritise their health without excessive sacrifices to their quality of life.
Non-invasive treatments provide effective solutions without requiring significant time, recovery, or compromise, empowering women to manage their health in a way that is both practical and respectful of their responsibilities.
The future of women’s health lies in technologies that allow for individualised, nonintrusive care.
Rather than forcing women to choose between their health and their quality of life, non-invasive treatments allow women to have both by providing effective solutions that don’t demand significant time, recovery, or compromise.
This shift is not just about better healthcare; it’s about a better approach to healthcare that respects women’s needs and preferences and redefines what it means to live well.
Non-invasive treatments recognise that quality of life is more than symptom management and entails supporting a woman’s ability to thrive in all areas of her life without being held back by the limitations of more traditional medical treatments.
Gloria Kolb is the CEO and co-founder of Elitone, the first non-invasive, FDA-cleared, wearable treatment for women with urinary incontinence. Elitone’s accolades include winning Best New Product by My Face My Body, Sling Shot 2020, CES Innovation Award, and many startup competitions. As an inventor with 30+ patents, Gloria has been featured in Forbes as a Top Scientist Driving Innovation in Women’s Health. Her creative designs and problem-solving abilities have earned her recognition, such as Boston’s “40 Under 40” and MIT Review’s “World’s Top Innovators under 35.” She has engineering degrees from MIT and Stanford, as well as an MBA in entrepreneurship from Babson College.
Insight
New pregnancy treatment shows promise for at-risk twins

A high-powered ultrasound treatment could help identical twins affected by a rare and serious condition during early pregnancy, an initial study suggests.
Twin-to-twin transfusion syndrome, or TTTS, causes uneven blood flow between identical twins who share a placenta.
The imbalance can leave one baby dangerously small and the other too large, putting both babies’ survival at risk.
Brioney Garrett’s daughters were in danger before doctors used the world-first treatment to seal the blood vessels causing the problem without an operation.
Nancy and Margo were born healthy and, now aged four, are due to start school.
Researchers from Queen Charlotte’s and Chelsea Hospital tested the non-invasive procedure in 10 women from the UK and elsewhere in Europe after scans detected TTTS during early pregnancy.
Five women needed further treatment, while 12 of the 20 babies survived following the procedure.
The researchers described having a treatment that did not require a needle or telescope to be inserted into the mother’s abdomen as “extremely exciting”.
However, they said larger studies involving more pregnant women were needed before the procedure could be offered more widely.
Garrett described her daughters as “my miracle twins”.
She said: “We were in a very dire situation and I don’t forget that.
“It stays with me always how things could have been. Every day I still count my blessings.”
TTTS affects between 10 and 15 per cent of identical twins who share a placenta, representing around 300 to 400 pregnancies in the UK each year.
The uneven blood flow causes excess fluid to build up around the larger recipient baby, while leaving dangerously little fluid around the smaller donor baby.
Treatment usually involves inserting a needle into the womb to drain some of the fluid or using a laser to seal the connecting blood vessels.
Garrett’s procedure took about 20 minutes. She lay flat while a specially designed machine directed high-powered ultrasound waves at small blood vessels in her placenta.
She said: “It was very quick and pretty painless.”
Christoph Lees, head of fetal medicine at Imperial College Healthcare NHS Trust and professor of obstetrics at Imperial College London, described the research as “very promising”.
He said: “If this could work in a fully-fledged study, it could give hope to a lot of women who otherwise might have to have quite invasive treatment.”
Ultrasound is commonly used during medical scans to produce images of the body, but this procedure uses much more focused waves.
Heat generated by the waves can seal blood vessels about 2mm in diameter and located around 5cm to 6cm beneath the skin.
The procedure blocked blood flow in 90 per cent of the vessels treated during the study, with no unwanted side-effects reported.
Twins Trust, which supported the study, said the approach could make a significant difference for families affected by TTTS.
Helen Peck, head of healthcare engagement and research, said: “Any procedure that is non-invasive and can potentially identify TTTS earlier and improve outcomes for our families with this life-threatening condition could be a turning point.”
Scans carried out weeks after Garrett’s procedure showed that blood flow between the babies had been rebalanced, although other problems developed during the pregnancy.
Garrett said Margo, who had too little fluid around her, “was in a much better position” and that “the strain on Nancy’s heart had eased”.
Nancy and Margo were born at nearly 34 weeks, weighing 3lb 7oz and 3lb 3oz respectively.
Garrett said: “They were both healthy, and Margo wasn’t as small as we worried she was going to be.”
The twins are due to start primary school in September.
Garrett said: “They’re funny, smart, energetic little girls that just fit right in with their age group.”
Insight
Breast cancer rising rapidly in Asian American women, study finds

Breast cancer rates have risen rapidly among Asian American women over the past two decades, with some of the steepest increases among women under 50, new research has revealed.
Rates rose by more than three per cent a year in nearly every Asian American ethnic group studied, much faster than in any other US ethnic group.
The increase was particularly marked among women under 50 and in cases involving advanced-stage disease or certain aggressive subtypes of the cancer.
The study found even larger increases among Chinese and Vietnamese women.
Breast cancer rates among Native Hawaiian women were already among the highest recorded among US women, but rose by about one per cent a year, less than the increases seen in Asian American groups.
The researchers said increased screening was unlikely to explain the trend because screening would be expected to identify more cancers at an earlier stage.
Instead, cancers that had already spread increased at the fastest rate.
Triple-negative breast cancer, considered the most aggressive subtype, rose by more than six per cent a year among Chinese American women between 2017 and 2022.
Scarlett Lin Gomez, senior author and professor of epidemiology and biostatistics at the University of California, San Francisco, said: “These patterns are highly concerning from a disparities standpoint.
“They underscore why it is so important to move beyond treating Asian Americans, Native Hawaiians, and Pacific Islanders as a single population.”
Researchers analysed about 150,000 cases of invasive breast cancer diagnosed between 2000 and 2022 using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results Programme.
The analysis covered nine Asian American, Native Hawaiian and Pacific Islander populations across 14 states. Together, these states account for about two-thirds of the US population within these groups.
Except for Native Hawaiian women, Asian American women have historically had lower breast cancer rates than non-Hispanic white women.
However, the gap has narrowed rapidly. By 2022, incidence among Asian American women under 50 was comparable with that recorded among white women.
The reasons for the increase among women under 50 remain unclear.
Changes in reproductive patterns, diet and other lifestyle factors may play a part, but researchers said they did not fully explain the findings.
They said previously unidentified risk factors may also be contributing to the rises in some Asian American communities.
Researchers hope two UCSF-based studies, the CRANE breast cancer study and the ASPIRE cohort study, will provide insights into these factors.
Gomez said: “Understanding why breast cancer is increasing so rapidly in these communities is critical.
“At the same time, we need to ensure that women across all Asian American, Native Hawaiian, and Pacific Islander communities have access to culturally appropriate education, screening, and timely follow-up care.”
Insight
Softening ovaries could extend fertility as women age, study suggests

Softening ageing ovaries could help women remain fertile for longer, early animal research suggests.
Fertility declines with age for several reasons, including poorer egg quality, fewer ovarian follicles and the gradual stiffening of ovarian tissue.
Existing fertility treatments, including hormone therapy and in vitro fertilisation, mainly address hormonal imbalances or help eggs mature or become fertilised.
Scientists are now examining whether changing the physical structure of the ovaries could provide another route for future fertility treatments.
Stuart A. Cook, of the Cardiovascular and Metabolic Disorders Programme at Duke-National University of Singapore Medical School, published an accompanying commentary on the research.
Researchers led by Shixuan Wang at Huazhong University of Science and Technology in Wuhan, China, collected healthy ovarian tissue from younger, middle-aged and older women.
They also examined samples from patients with polycystic ovary syndrome, known as PCOS, premature ovarian insufficiency, or POI, and endometriosis.
PCOS is a hormonal condition that can disrupt ovulation. POI occurs when the ovaries stop working normally before the age of 40, while endometriosis causes tissue similar to the womb lining to grow elsewhere in the body.
Tests of protein levels and gene activity found higher levels of the inflammatory protein interleukin-11, or IL-11, in ageing and diseased ovaries.
In laboratory experiments, the researchers exposed ovarian fibroblasts to IL-11. Fibroblasts are cells that produce connective tissue.
The protein caused the cells to produce excess collagen, a structural material that can build up during scarring and make tissue stiffer.
The researchers then genetically modified mice so they could not respond to IL-11. The animals developed less ovarian stiffening and maintained better ovarian function as they aged.
Similar results were seen in mouse models of PCOS and POI caused by chemotherapy.
In the final part of the experiment, older mice and rats were injected with a nanoparticle treatment containing small interfering RNA, or siRNA, designed to switch off IL-11.
The treatment made the animals’ ovaries less stiff and improved fertility.
Pregnancy rates among older mice rose from 25 per cent to 50 per cent, while average litter sizes also increased.
More rats treated with the therapy became pregnant and produced larger litters.
The approach remains highly speculative and will require considerably more research before its safety or effectiveness in women can be established.
However, the researchers said blocking the inflammatory pathway could eventually form the basis of new fertility treatments.
They said: “We propose that anti-IL-11 therapy represents a promising translational strategy for delaying ovarian ageing.”
Insight1 week agoWomen with PMOS should have annual NHS checks, new guidance says
Diagnosis1 week agoTwo “gamechanger” tests set to speed up endometriosis diagnosis on the NHS
Cancer7 days agoThousands of women could avoid painful cancer exam with new AI blood test
Entrepreneur2 weeks agoKorea’s Femtech Industry Goes Global as Vespexx Hosts Korea Femtech Summit 2026
News2 weeks agoBreast cancer biosensor and low-cost ultrasound startups win women’s health AI competition
News2 weeks agoClue spotlights seven women’s health journeys in new campaign
Entrepreneur6 days agoApplications open for the third W Accelerate with Merck KGaA and M Ventures
Fertility1 week agoOlder women face lower chance of fertility treatment working, even with donor eggs, study finds













